Skyrizi(risankizumab)
Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis and psoriatic arthritis. It is known to target interleukin-23 subunit alpha.
Download report
Favorite
COVID-19
FDA Novel Drug Approvals 2019
Top 200 Pharmaceuticals by Retail Sales
Commercial
Trade Name
FDA
EMA
Skyrizi
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Risankizumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Skyrizi | risankizumab-rzaa | AbbVie | N-761105 RX | 2021-04-26 | 6 products |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| skyrizi | Biologic Licensing Application | 2020-12-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| psoriasis | EFO_0000676 | D011565 | L40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | 2 | 4 | 18 | 3 | 2 | 29 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | 2 | 4 | — | 1 | 8 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | 2 | 2 | — | — | 5 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | 1 | 2 | — | 1 | 4 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | U07.1 | — | 1 | — | — | — | 1 | |
| Hidradenitis suppurativa | D017497 | L73.2 | — | 1 | — | — | — | 1 | |
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | — | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | 1 | — | — | — | 1 |
| Ankylosing spondylitis | D013167 | EFO_0003898 | M45 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 9 | — | — | — | — | 9 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RISANKIZUMAB |
| INN | risankizumab |
| Description | Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody targeting interleukin 23A (IL-23A). Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie. Risankizumab has been approved in the European Union, the United States, and Canada for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and moderate to severe Crohn's disease in the United States. In Japan, it is approved for treating plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adults who have an inadequate response to conventional therapies.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | 1612838-76-2 |
| RxCUI | 2166040 |
| ChEMBL ID | CHEMBL3990029 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14762 |
| UNII ID | 90ZX3Q3FR7 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
IL23A
IL23A
Organism
Homo sapiens
Gene name
IL23A
Gene synonyms
SGRF
NCBI Gene ID
Protein name
interleukin-23 subunit alpha
Protein synonyms
IL-23 subunit alpha, IL-23-A, IL-23p19, interleukin 23 p19 subunit, interleukin 23, alpha subunit p19, Interleukin-23 subunit p19, interleukin-six, G-CSF related factor, JKA3 induced upon T-cell activation
Uniprot ID
Mouse ortholog
Il23a (83430)
interleukin-23 subunit alpha (Q9EQ14)
Variants
Clinical Variant
No data
Financial
Skyrizi - AbbVie
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,316 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
890 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more